Dr. Marroquin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5841 S. Maryland Ave.
Chicago, IL 60637
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2022 - 2025
Icahn School of Medicine at Mount Sinai/Morningside/WestChief Residency, Internal Medicine, 2021 - 2022- Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 2018 - 2021
Johns Hopkins UniversityPost-Doctoral Fellowship, Hematology and Medical Oncology, 2016 - 2018
Tecnologico de Monterrey Escuela de MedicinaClass of 2017
Certifications & Licensure
IL State Medical License 2022 - 2026- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia.Rafael Madero-Marroquin, Ryan W Hunter, Caner Saygin, Hannah Johnston, Adam S DuVall
Ejhaem. 2025-02-01 - Imetelstat: Drugging Telomerase in Transfusion-Dependent Low and Intermediate-1 Risk MDS.Joseph Michael Cannova, Rafael Madero-Marroquin, Olatoyosi Odenike
Blood Advances. 2025-01-07 - Correction to: Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome.Muriel R Battaglia, Joseph Cannova, Rafael Madero-Marroquin, Anand A Patel
Current Treatment Options in Oncology. 2024-10-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
